Society for Pediatric Dermatology

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.

Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.

New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

Take our latest 5-question quiz based on the recommended strategies of laboratory-based diagnosis of epidermolysis bullosa.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.

With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

In recognition of the Pre-AAD 2024 meeting, take our quiz based on Society for Pediatric Dermatology resources.

Boiko discusses the annual weeklong summer camp for children and adolescents with skin diseases to make connections, experience camp with the support of volunteer specialists, and find comfort with their condition.

Peter Marinkovich, MD, reflects on the significant growth in advanced therapy development, particularly in rare skin diseases.

The FDA approved the first 2 therapies to treat molluscum contagiosum in the last year. Silver explains how it's provided more than just treatment options.

Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.

Marinkovich discusses how the investigative cell-based graft therapy may serve a key role in the emerging DEB treatment paradigm.

In recognition of the Pre-AAD 2024 meeting, take our quiz based on Society for Pediatric Dermatology resources.

Lio shares 3 aspects of pain management that dermatologists can consider to improve the experience of procedures for patients.

Joyce Teng, MD, PhD, reviews a pair of recently approved agents for DEB—as well as a cell therapy awaiting FDA decision this year.

Gene and cell therapies are reaching patients with the severe forms of epidermolysis bullosa. An expert explains their differing benefits and strengths.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

Dr. Karan Lal speaks on treating vitiligo in patients from across the world, and how he expects a wave of prescription requests for ruxolitinib cream following the potential FDA approval.